Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744053 · ClinicalTrials.gov registry record · Early Phase 1
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
A Early Phase 1 study of HER2/Neu Negative and Triple-Negative Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 96
- Enrollment target
- 6
- Study locations
NCT02744053: Active Early Phase 1 study of HER2/Neu Negative and Triple-Negative Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT02744053 is a Early Phase 1 study of HER2/Neu Negative and Triple-Negative Breast Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 96 participants, below the 164-participant average among 28 other HER2/Neu Negative trials with a reported enrollment target (41% lower). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02744053, a Early Phase 1 study of HER2/Neu Negative and Triple-Negative Breast Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 96 participants
- Enrollment target
- 6
- Study locations
Study Summary
This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI may help researchers predict which patients may respond to treatment.
Primary Outcome
The ability to assess and predict response will be compared among the imaging modalities and with standard pathological evaluation. These volume changes will be correlated with residual cancer burden (RCB) status after surgery and will be used to classify patients into predicted responder or non-responder categories. Predictive accuracies among the imaging modalities will be compared using paired ROC curve analyses.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- RADIATION Scintimammography
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- DRUG Technetium Tc-99m Sestamibi
Study Locations (6)
Texas
- Memorial Hermann Memorial City Medical Center - Houston
- M D Anderson Cancer Center - Houston
- MD Anderson in Katy - Houston
- MD Anderson League City - Nassau Bay
- MD Anderson in Sugar Land - Sugar Land
- MD Anderson in The Woodlands - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-11-07 |
| Est. Completion | 2026-04-30 |
| Phase | Early Phase 1 |
What the registry record for NCT02744053 still lists
NCT02744053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 164-participant average among 28 other HER2/Neu Negative trials with a reported enrollment target (41% lower).
The record links to 4 conditions, with HER2/Neu Negative appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02744053 lists 6 locations in 1 state (Texas).
Frequently Asked Questions
What is clinical trial NCT02744053 about?
NCT02744053 is a clinical study titled "DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer". This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemothera...
What is the current status of trial NCT02744053?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 96 participants. The study started on 2016-11-07. Estimated completion is 2026-04-30.
What conditions does trial NCT02744053 study?
This clinical trial studies the following conditions: HER2/Neu Negative, Triple-Negative Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative.
What interventions are being tested in trial NCT02744053?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Scintimammography (RADIATION), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Technetium Tc-99m Sestamibi (DRUG).
Who is sponsoring clinical trial NCT02744053?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02744053 being conducted?
This trial has 6 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2/Neu Negative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02744053's enrollment target sits among peer trials
96 11th of 28 higher than 18 of 28 other HER2/Neu Negative trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2/Neu Negative trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
RECRUITING · NA
-
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
RECRUITING · NA
-
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
RECRUITING · Phase 2
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI